Aspirin and NSAIDs for breast cancer chemoprevention

European Journal of Cancer Prevention

Volumn 24, Issue 5, 2015, Pages 416-421

  Yiannakopoulou, Eugenia Ch ^a  

^a UNIVERSITY OF WEST ATTICA   (Greece)

Author keywords

aspirin; breast cancer; mechanisms of action; NSAIDs; salicylates

Indexed keywords

ACETYLSALICYLIC ACID; ANACARDIC ACID; BETA CATENIN; CARCINOGEN; CELECOXIB; CHECKPOINT KINASE 2; CYCLIC GMP; CYCLIN D1; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FIBROBLAST GROWTH FACTOR 2; IBUPROFEN; INDOMETACIN; INTERLEUKIN 10; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE V; PROTEIN P53; SALICYLIC ACID; SALICYLIC ACID DERIVATIVE; SULINDAC; SULINDAC SULFIDE; SURVIVIN; WNT PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CELL CYCLE PROGRESSION; CHEMOPROPHYLAXIS; DNA ADDUCT; DNA BINDING; HUMAN; IMMUNOMODULATION; IMMUNOSURVEILLANCE; INTRACELLULAR SPACE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; BREAST NEOPLASMS; FEMALE; PROGNOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BREAST NEOPLASMS; FEMALE; HUMANS; PROGNOSIS;

EID: 84938954215     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000098     Document Type: Review

References (33)

1. Abbadessa G, Spaccamiglio A, Sartori ML, Nebbia C, Dacasto M, Di Carlo F, Racca S (2006). The aspirin metabolite, salicylate, inhibits 7,12-dimethylbenz [a]anthracene-DNA adduct formation in breast cancer cells. Int J Oncol 28:1131-1140.
2. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE (2001). Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 21:3425-3432.
3. Adachi M, Sakamoto H, Kawamura R, Wang W, Imai K, Shinomura Y (2007). Nonsteroidal anti-inflammatory drugs and oxidative stress in cancer cells. Histol Histopathol 22:437-442.
4. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE (2000). Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 7:1377-1381.
5. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P (2004). Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2:632-642.
6. Bau JT, Kurz EU (2011). Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha. Biochem Pharmacol 81:345-354.
7. Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH (2010). Non steroidal anti-inflammatory drug use (NSAID) and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 9:1503-1512.
8. Bronger H, Kraeft S, Schwarz-Boeger U, Cerny C, Stöckel A, Avril S, et al. (2012). Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. Breast Cancer Res 14:R30.
9. Burnett GT, Weathersby DC, Taylor TE, Bremner TA (2008). Regulation of inflammation- and angiogenesis-related gene expression in breast cancer cells and co-cultured macrophages. Anticancer Res 28:2093-2099.
10. Carter CA, Milholland RJ, Shea W, Ip MM (1983). Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthraceneinduced mammary tumorigenesis in rats fed different levels of fat. Cancer Res 4:3559-3562.
11. Carter CA, Ip MM, Ip C (1989). A comparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7,12-dimethylbenz[a] anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acid. Carcinogenesis 10:1369-1374.
12. Harris RE, Alshafie GA, Abou-Issa H, Seibert K (2000). Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60:2101-2103.
13. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, et al. Womens Health Initiative (2003). Breast cancer and nonsteroidal antiinflammatory drugs: prospective results from the Womens Health Initiative. Cancer Res 63:6096-6101.
14. Kwan ML, Habel LA, Slattery ML, Caan B (2007). NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 18:613-620.
15. Li X, Gao L, Cui Q, Gary BD, Dyess DL, Taylor W, et al. (2012). Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs. Oncogene 31:4979-4986.
16. McCormick DL, Madigan MJ, Moon RC (1985). Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res 45:1803-1808.
17. Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, et al. (2000). Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 91:886-892.
18. Nath N, Vassell R, Chattopadhyay M, Kogan M, Kashfi K (2009). Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling. Biochem Pharmacol 78:1298-1304.
19. Noguchi M, Taniya T, Koyasaki N, Kumaki T, Miyazaki I, Mizukami Y (1991). Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor contents of 7,12-dimethylbenz (a)anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high- or low-fat diet. Cancer Res 51:2683-2689.
20. Robertson FM, Parrett ML, Joarder FS, Ross M, Abou-Issa HM, Alshafie G, Harris RE (1998). Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 122:165-175.
21. Schultz DJ, Wickramasinghe NS, Ivanova MM, Isaacs SM, Dougherty SM, Imbert- Fernandez Y, et al. (2010). Anacardic acid inhibits estrogen receptor alpha- DNA binding and reduces target gene transcription and breast cancer cell proliferation. Mol Cancer Ther 9:594-605.
22. Seo AM, Hong SW, Shin JS, Park IC, Hong NJ, Kim DJ, et al. (2009). Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKbeta. Apoptosis 14:913-922.
23. Spitz GA, Furtado CM, Sola-Penna M, Zancan P (2009). Acetylsalicylic acid and salicylic acid decrease tumor cell viability and glucose metabolism modulating 6-phosphofructo-1-kinase structure and activity. Biochem Pharmacol 77:46-53.
24. Tafani M, Russo A, Di Vito M, Sale P, Pellegrini L, Schito L, et al. (2010). Upregulation of pro-inflammatory genes as adaptation to hypoxia in MCF-7 cells and in human mammary invasive carcinoma microenvironment. Cancer Sci 101:1014-1023.
25. Takkouche B, Regueira-Méndez C, Etminan M (2008). Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100:1439-1447.
26. Teh SH, Hill AK, Foley DA, McDermott EW, OHiggins NJ, Young LS (2004). COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells. J Cell Biochem 91:796-807.
27. Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC, Piazza GA (2009). Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther 8:3331-3340.
28. Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC, Piazza GA (2011). Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila) 4:1275-1284.
29. Van Aswegen C, Dirksen van Schalkwyk JC, Roux LJ, Becker PJ, Du Plessis DJ (1992). A novel study on the effect of acetylsalicylic acid on the binding capacity of estrogen receptors from MCF-7 cells. Clin Physiol Biochem 9:145-149.
30. Wang L, Liu LH, Shan BE, Zhang C, Sang MX, Li J (2009). Celecoxib promotes apoptosis of breast cancer cell line MDA-MB-231 through down-regulation of the NF-kappaB pathway. Ai Zheng 28:569-574.
31. Williams JL, Ji P, Ouyang N, Liu X, Rigas B (2008). NO-donating aspirin inhibits the activation of NF-kappaB in human cancer cell lines and Min mice. Carcinogenesis 29:390-397.
32. Yan F, He Q, Hu X, Li W, Wei K, Li L, et al. (2013). Direct regulation of caspase-3 by the transcription factor AP-2 is involved in aspirin-induced apoptosis in MDA-MB-453 breast cancer cells. Mol Med Rep 7:909-914.
33. Yiannakopoulou E (2012). Modulation of lymphangiogenesis: a new target for aspirin and other nonsteroidal anti-inflammatory agents? A systematic review. J Clin Pharmacol 52:1749-1754.